UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus UPDATE

UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus

Funding provided by the National Institute of Allergy and Infectious Diseases

Seattle, WA August 18, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs announced in July that it received funding to expand testing of its broad spectrum innate immune antivirals against Zika virus. This project is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Department of Health and Human Services. This supplemental contract award will be used to evaluate lead broad spectrum antivirals in preclinical models of Zika virus infection.

Zika virus has been named as a global public health emergency by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). “There is a critical need for therapeutics to combat emerging viruses like Zika that are creating a public health crisis across the globe”, said Dr. Shawn Iadonato, Kineta CEO. “We are eager to expand testing of our broad spectrum antivirals in Zika virus, as they have shown compelling preclinical efficacy in other flaviviruses such as Dengue and West Nile virus and have the potential for long term development as a pan-flavivirus therapy.”


This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201500011C.

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual Meeting

Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual Meeting

Data highlighting distinct immunological activation patterns of Kineta’s vaccine adjuvants presented

Seattle, WA May 16, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs presented promising new data on Kineta’s vaccine adjuvant program at the American Association of Immunologists annual meeting in Seattle, WA.

Dr. Peter Probst, Director and Head of Immunology, presented data demonstrating the unique protective immune response of Kineta’s vaccine adjuvants and dose sparing efficacy achieved in vivo. Kineta’s lead adjuvant is being developed in combination with H5N1 influenza antigens to provide a safe and more efficacious vaccine.

“We are very excited to have a strong presence at the Immunology 2016 conference with multiple presentations on Kineta’s vaccine adjuvant program,” stated Kristin Bedard, VP R&D and Head of Virology at Kineta. “Our immune modulating vaccine adjuvants were discovered using Kineta’s AViiD™ screening platform. This proprietary platform identifies small molecules that trigger an IRF-3 response – a novel target for immune modulating adjuvants and therapeutics.”

About Kineta’s Vaccine Adjuvant Program

Kineta is developing novel immune modulating adjuvants that enhance the efficacy of existing vaccines through a balanced immune response while using lower vaccine doses. The lead compound is in preclinical development. It was discovered through Kineta’s proprietary AViid™ discovery platform which is focused on screening for small molecules that activate IRF-3 dependent innate immune pathways. Kineta’s vaccine adjuvants provide a targeted approach that safely stimulates innate immune protective pathways. This adjuvant system targets highly pathogenic avian influenza infection and may have application in other critical infectious diseases. This program is conducted in collaboration with the National Institutes of Health (NIH) and University of Washington.

About Kineta

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, intellectual property protection and enforcement, efficacy and demand for our products, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and changes in legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials

Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials

Seattle, WA May 5, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel immune modulating and antiviral drugs announced today that the company will receive a Wellcome Trust Translation Fund Award of up to $7.2M. This award will advance the development of a novel antiviral therapy to treat Lassa haemorrhagic fever.

The funded collaboration will enable manufacturing, preclinical development, regulatory filings and first in human clinical studies for the antiviral lead LHF-535. Preclinical milestones include characterizing the efficacy of LHF-535 against Lassa fever in animal models and completing IND-enabling toxicology studies. The goal of the collaboration is to complete Phase 1a and Phase 1b safety studies in human subjects and position LHF-535 for Phase 2 evaluation in Lassa fever patients where no approved treatment is currently available.

“We are excited to collaborate with the Wellcome Trust on our Lassa fever program. They are a global leader in supporting research and improving health in infectious diseases, and we are honored to join the community of Wellcome Trust researchers”, said Kineta’s CEO, Shawn Iadonato. “This Translation Fund Award positions us to complete the Phase I program for LHF-535 and prepare for studies to evaluate the efficacy of this novel medicine to treat Lassa fever, a viral disease with no approved treatment options,” Dr. Iadonato added.

About LHF-535

LHF-535 is a small molecule antiviral with potent activity against Lassa and other arenaviruses. It inhibits virus entry into target host cells and serves to suppress viral replication. LHF-535 is an optimized lead compound with good oral bioavailability and pharmacokinetics, supporting once-daily administration. It has demonstrated safety and efficacy in preclinical models, including reduced virus titers and enhanced survival in animal models of arenavirus pathogenesis. A clear development path for LHF-535 was established after a successful pre-IND interaction with FDA in mid-2015.

About Lassa Fever

Lassa fever is an acute viral illness that is known to be endemic in Benin, Guinea, Liberia, Sierra Leone and parts of Nigeria, but probably exists in other West African countries as well.1 Lassa fever causes 100,000-300,000 infections and is responsible for ~5000 deaths annually in West Africa. Death rates are particularly high for women in the third trimester of pregnancy, and fetal loss occurs in nearly all infected pregnant women.2 The Lassa virus is transmitted to humans via contact with food or household items contaminated with rodent urine or feces. Person-to-person transmission also occurs, particularly in hospitals lacking adequate infection control measures.1

References:
1. WHO Lassa Fever Fact Sheet http://www.who.int/mediacentre/factsheets/fs179/en/
2. CDC Lassa Fever Fact Sheet http://www.cdc.gov/vhf/lassa/pdf/factsheet.pdf


Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.kinetabio.com

The Wellcome Trust is a global charitable foundation dedicated to improving health. We support bright minds in science, the humanities and the social sciences, as well as education, public engagement and the application of research to medicine. Our investment portfolio gives us the independence to support such transformative work as the sequencing and understanding of the human genome, research that established front-line drugs for malaria, and Wellcome Collection, our free venue for the incurably curious that explores medicine, life and art.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals

Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals

Proprietary AViiD™ screening platform highlighted

Seattle, WA April 22, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs presented promising new data on two of Kineta’s antiviral programs at the 29th International Conference on Antiviral Research in La Jolla, CA this week.

Dr. Sean Amberg, Director of Biodefense Initiatives, presented new data on Kineta’s novel direct acting antiviral for Lassa fever. LHF-535 demonstrated potent antiviral activity across broad arenaviruses including the lead indication Lassa fever virus. Additionally, LHF-535 showed significant reduction in virus titers and improved survival in arenavirus animal models at a daily oral dose of 10 mg/kg. The clinical candidate has a favorable tolerability profile and is planned to enter clinical testing as a first in class oral therapeutic for Lassa fever patients.

Dr. Shari Kaiser, Senior Scientist (Virology), presented on Kineta’s AViiD™ screening platform and broad spectrum innate immune antivirals. Dr. Kaiser will present the proprietary drug screening platform used to identify lead candidates for vaccine adjuvants, antiviral therapeutics and immune modulators for oncology treatment. The lead series of antivirals demonstrated broad in vitro potency against respiratory and emerging viruses including Ebola and diverse flaviviruses. Additionally, proof of concept in vivo data presented by Dr. Kaiser confirms the potent antiviral activity against influenza and dengue virus.

“We are very pleased with the progress of LHF-535 and our broad spectrum innate immune antiviral program”, stated Kristin Bedard, VP R&D and Head of Virology at Kineta. “Kineta was invited to present on several of our programs at ICAR this week which is tremendous validation of our antiviral research and development efforts.”

About LHF-535

LHF-535 is a small molecule antiviral with potent activity against Lassa and other arenaviruses. It inhibits virus entry into target host cells and serves to suppress viral replication. LHF-535 is an optimized lead compound with good oral bioavailability and pharmacokinetics, supporting once-daily administration. It has demonstrated safety in preclinical models and is effective in animal models of arenavirus pathogenesis. A clear development path toward an IND (Investigational New Drug) application for LHF-535 was established after a successful interaction with FDA in mid-2015.

About Kineta’s Innate Immune Antivirals

Kineta’s Innate Immune Antiviral program offers a proprietary discovery platform and compounds with a novel mechanism of action that activate the innate immune transcription factor IRF-3, a critical first responder that is essential for inhibiting viral replication and clearing infection. Unlike direct acting antivirals, Kineta’s host directed compounds have demonstrated efficacy across a broad spectrum of respiratory, hepatitis and emerging viruses and offer the potential for a pan-viral therapy that circumvents drug resistance. No equivalent drug currently exists in the market.

About Kineta

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic Flu

Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic Flu

Potential application in other critical infectious diseases

SEATTLE, WA, March 31, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs announced promising new data demonstrating KIN 1148 enhances the efficacy of existing influenza vaccines in animal models through a balanced immune response. Additionally, enhanced effectiveness with KIN 1148 was achieved while using lower vaccine doses. Kineta’s vaccine adjuvants are small molecule compounds added to a vaccine to improve the body’s vaccine immune response. The data were presented by Dr. Kristin Bedard, Kineta’s Vice President of Research and Development, during a presentation at the 16th Annual World Vaccine Congress in Washington DC.

“KIN 1148 is a novel vaccine adjuvant that targets IRF-3 innate immune pathways with the potential to induce a protective immune response, boost neutralizing antibodies and reduce inflammation” Dr. Bedard stated. “It provides a >15-fold dose sparing effect which can maximize the crucial supply of influenza split vaccines.”

About KIN 1148 – Vaccine Adjuvant System

Kineta’s vaccine development group has identified novel immune modulating adjuvants that enhance the efficacy of existing vaccines through a balanced immune response while using lower vaccine doses. KIN 1148 is the lead compound that is in preclinical development. It was discovered through Kineta’s proprietary AViiD™ discovery platform which is focused on screening for small molecules that activate IRF-3 dependent innate immune pathways. KIN 1148 provides a targeted approach that safely stimulates innate immune protective pathways. The KIN 1148 adjuvant system targets highly pathogenic avian influenza infection and may have application in other critical infectious diseases. This program is conducted in collaboration with the National Institutes of Health (NIH) and University of Washington.

About Kineta

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress

Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress

New data in highly pathogenic influenza to be highlighted

Seattle, WA March 22, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs announced today it will present new data on Kineta’s vaccine adjuvant program at the 16th Annual World Vaccine Congress in Washington DC. Dr. Kristin Bedard, Vice President R&D and Head of Virology, will be presenting during the Influenza and Respiratory Vaccines segment of the Congress on March 30th at 5:40PM. Dr. Bedard will be presenting new preclinical data on KIN 1148, Kineta’s novel vaccine adjuvant system for highly pathogenic influenza infections.

About KIN 1148 – Vaccine Adjuvant System

Kineta’s vaccine development group has identified novel immune modulating adjuvants that enhance the efficacy of existing vaccines through a balanced immune response while using lower vaccine doses. KIN 1148 is the lead compound that is in preclinical development. It was discovered through Kineta’s proprietary AViiD™ discovery platform which is focused on screening for small molecules that activate IRF-3 dependent innate immune pathways. KIN 1148 provides a targeted approach that safely stimulates innate immune protective pathways. The KIN 1148 adjuvant system targets highly pathogenic avian influenza infection and may have application in other critical infectious diseases. This program is conducted in collaboration with the National Institutes of Health (NIH) and University of Washington.

About Kineta

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website,, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.